The complaint alleges that Insulet Corporation violated the Securities Exchange Act of 1934 by concealing the true extent of manufacturing control failures. According to the filing, the company’s March 2026 medical device correction affected a significantly larger volume of Pod products than previously disclosed to the market. These omissions purportedly led to artificial inflation of the company's share price, causing financial losses for investors once the full scale of the manufacturing issues surfaced.

Shareholders who incurred losses during the class period are eligible to participate in the recovery effort without paying out-of-pocket legal fees. While the class has not yet been certified, individuals may choose to serve as a lead plaintiff to represent the collective interest of shareholders. Brian Schall and David Schwartz are managing inquiries for the firm at their Los Angeles office, noting that those who choose to take no action will remain as absent class members.